Cox Capital Mgt LLC Has $1.21 Million Position in Novo Nordisk A/S (NYSE:NVO)

Cox Capital Mgt LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,092 shares of the company’s stock after selling 1,348 shares during the quarter. Cox Capital Mgt LLC’s holdings in Novo Nordisk A/S were worth $1,212,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the period. DSM Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $98,765,000. Marshall Wace LLP lifted its stake in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after acquiring an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Novo Nordisk A/S in the third quarter valued at approximately $42,017,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 4.0 %

Shares of NYSE:NVO opened at $81.27 on Wednesday. The firm has a market cap of $364.70 billion, a P/E ratio of 26.30, a PEG ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $80.05 and a 52-week high of $148.15. The business’s 50 day simple moving average is $99.26 and its two-hundred day simple moving average is $118.18. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.